LENZ Therapeutics Inc (LENZ NASDAQ) stock market data APIs
$41.9751
-0.26(-0.6%)
as of September 17, 2025
Try our APIs with
free plan!
LENZ Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Prev. Close
41.9751
Open
41.7114
High
42.6577
Low
40.9224
52 wk Range
16.535-42.77
Market Cap
1 178 M
Shares Outstanding
28 522 K
Revenue
5 000 K
EPS
-0.53
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with LENZ Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get LENZ Therapeutics Inc data using free add-ons & libraries
Get LENZ Therapeutics Inc Fundamental Data
LENZ Therapeutics Inc Fundamental data includes:
- Net Revenue: 5 000 K
- EBITDA: -61 868 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-30
- EPS/Forecast: -0.61
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
LENZ Therapeutics Inc News
New
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright
Investing.com - H.C. Wainwright raised its price target on LENZ Therapeutics Inc (NASDAQ:LENZ) to $56.00 from $48.00 on Friday, while maintaining a Buy rating on the stock. The company, currently trad...
First Week of April 2026 Options Trading For Lenz Therapeutics
Investors in Lenz Therapeutics Inc New (Symbol: LENZ) saw new options begin trading this week, for the April 2026 expiration. One of the key data points that goes into the price an option buyer is wi...
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright
Investing.com - H.C. Wainwright raised its price target on LENZ Therapeutics Inc (NASDAQ:LENZ) to $56.00 from $48.00 on Monday, while maintaining a Buy rating on the stock. The company, currently valu...
LENZ Therapeutics gets FDA nod for presbyopia eye drop
[Female scientist examining toxic liquid in laboratory.] skynesher/E+ via Getty Images * LENZ Therapeutics (NASDAQ:LENZ [https://seekingalpha.com/symbol/LENZ]) said that the U.S. FDA approved its e...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
